Cremers, S., Arnold, S. L. M., Kshirsagar, N. A., Waitt, C., Ogunleye, O. O., & Gustafsson, L. L. (2025). Appraising the visibility, relevance and impacts of clinical pharmacology. British Journal of Clinical Pharmacology. Portico. https://doi.org/10.1002/bcp.70074

Myers, J. T., Yamaguchi, A., Vo, A. T., Dasari, A., Battiwala, A., Patel, N., Fung, L. C., Gonen, O. M., Imran, M., Van Dam, J., Hashim, M. A., Dhalla, A. K., & Bilezikian, J. P. (2025). An oral robotic pill reliably and safely delivers teriparatide with high bioavailability in healthy volunteers: A phase 1 study. British Journal of Clinical Pharmacology. Portico. https://doi.org/10.1002/bcp.70064

Wexler, T. L., & Page‐Wilson, G. (2023). Dopamine agonists for the treatment of pituitary tumours: From ergot extracts to next generation therapies. British Journal of Clinical Pharmacology, 89(4), 1304–1317. Portico. https://doi.org/10.1111/bcp.15660

Lyashchenko, A. K., Yu, Y., McMahon, D. J., Bies, R., Yin, M. T., & Cremers, S. (2022). Systemic exposure to hydroxychloroquine and its relationship with outcome in severely ill COVID‐19 patients in New York City. British Journal of Clinical Pharmacology, 89(1), 299–315. Portico. https://doi.org/10.1111/bcp.15489

Goyal, P., Safford, M. M., Hilmer, S. N., Steinman, M. A., Matlock, D. D., Maurer, M. S., Lachs, M. S., & Kronish, I. M. (2022). N‐of‐1 trials to facilitate evidence‐based deprescribing: Rationale and case study. British Journal of Clinical Pharmacology, 88(10), 4460–4473. Portico. https://doi.org/10.1111/bcp.15442

Ganapathi, M., Campbell, P., Ofori, K., Aggarwal, V., Francis, R. O., & Kratz, A. (2022). Impact of pre‐emptive rapid testing for glucose‐6‐phosphate dehydrogenase deficiency prior to rasburicase administration at a tertiary care centre: A retrospective study. British Journal of Clinical Pharmacology, 88(9), 4163–4170. Portico. https://doi.org/10.1111/bcp.15353

Arout, C. A., Haney, M., Herrmann, E. S., Bedi, G., & Cooper, Z. D. (2021). A placebo‐controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. British Journal of Clinical Pharmacology, 88(1), 347–355. Portico. https://doi.org/10.1111/bcp.14973